Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Blink Reminders and Meibomian Gland Loss in Digital Screen Users

This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).

Participants needed: 28
Trial details
Age: 18-40Biological sex: AllType: InterventionalSponsor: Asociación para Evitar la Ceguera en MéxicoUpdated: Feb 27, 2026
Eligibility criteria

Participants aged 18 to 40 years. [+5]

Active ocular disease, including infections, corneal ulcers, or acute conjunctiv... [+5]

Status: Recruiting

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.

Participants needed: 12
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Asociación para Evitar la Ceguera en MéxicoUpdated: Dec 8, 2025Locations: 1
Eligibility criteria

Age ≥ 18 years. [+2]

Other corneal disease [+10]

Status: Recruiting

Safety and Tolerability of EO2002

The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.

Participants needed: 32
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Asociación para Evitar la Ceguera en MéxicoUpdated: Dec 8, 2025Locations: 1
Eligibility criteria

Age ≥ 18 years. [+2]

Other corneal disease [+10]

Status: Recruiting

Vascular Changes Associated With Endophthalmitis.

This study aims to describe and investigate vascular changes associated with exogenous endophthalmitis, as well as to create a photo library where they are evidenced

Participants needed: 71
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Asociación para Evitar la Ceguera en MéxicoUpdated: Sep 16, 2025Locations: 1Duration: 6 Weeks
Eligibility criteria

Patients with a history of endophthalmitis Diagnosis of Endophthalmitis [+4]

Patients who have not signed the informed consent [+2]

Status: Recruiting

Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment

This study aims to evaluate postsurgical functional changes in patients with advanced epiretinal membrane (ERM) (stages 3 and 4) by integrating a controlled macular detachment with a balanced salt solution to the conventional ERM peeling technique.

Participants needed: 36
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Asociación para Evitar la Ceguera en MéxicoUpdated: Jul 31, 2025Locations: 1
Eligibility criteria

Patients over 18 years of age. [+3]

Patients with a confirmed diagnosis of grade III or IV ERM by Optical Coherence... [+1]

Status: Recruiting

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity

Trial details
Phase: Phase 2, Phase 3Age: 1-12Biological sex: AllType: InterventionalSponsor: Asociación para Evitar la Ceguera en MéxicoUpdated: Jul 31, 2024Locations: 1
Eligibility criteria

Retinopathy of prematurity stages III, IV and V in which we can not treat with l...

PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER